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Neuroblastoma (NB), ganglioneuroblastoma (GNB) and ganglio-
neuroma (GN) are paediatric tumours arising from a common
neural crest derived precursor cell which fails to undergo com-
plete differentiation into neurons of the sympathetic ganglia or
chromaffin cells of the adrenal medulla. Several parameters
including age, proliferation rate, ploidy, MYCN amplification,
chromosome 1p deletion and Trk receptors’ expression definitely
help for a more precise clinicopathological characterization of
these neoplasias. However most of the different classifications
proposed for neuroblastic tumours take into great account the
histologic appearance (Castleberry, 1997; Katzenstein et al, 1998;
Shimada et al, 1999). In fact, a high degree of ganglionic differen-
tiation observed in GN is usually associated with a non-aggressive
phenotype. In contrast, NB with undifferentiated histology reflects
a more aggressive behaviour in most cases. Interestingly, at vari-
ance with most neoplasia of the adult, neuroblastoma tumours
retain in many cases the ability to differentiate (i.e., towards a
neuronal phenotype) in vivo (Bolande, 1985). Differentiation of
NB cell cultures towards a neuronal phenotype can also be
obtained in vitro by means of several factors (Albemayor and
Sidell, 1989; Thiele, 1991a). Probably because of its potential
therapeutic value, retinoic acid (RA) is one of the most frequently
used inducers of NB cell differentiation. RA operates through
three different RXR/RAR heterodimers to transduce its signals in
NB cells (Giannini et al, 1997).
HMGI and HMGY isoforms originate from an alternative
splicing of the same gene located on chromosome 6p21. The two
proteins only differ by the exclusive presence of 11 amino acids in
the HMGI molecule, that are supposed to act as a spacer between
the first and the second of the three ‘AT-hook’ DNA binding
domains (Johnson et al, 1989; Friedmann et al, 1993). We will
refer to this gene and to its gene products as HMGI(Y), unless we
want to discriminate between HMGI and HMGY isoforms. A third
HMGI family member, HMGI-C, is encoded by a different gene
(Manfioletti et al, 1991) which maps to chromosome 12q13–15
(Schoenmakers et al, 1995; Ishwad et al, 1997). The three proteins
are considered architectural transcription factors and are involved
in chromatin conformation functions and in regulating transcrip-
tion through several gene promoters (reviewed in Bustin and
Reeves, 1996). Expression of the HMGI gene family is prominent
during early stages of mammalian development, where they are
likely to play an important role in the regulation of cell prolifera-
tion and differentiation (Zhou et al, 1995; Chiappetta et al, 1996;
Hirning-Folz et al, 1998). This is clearly suggested by the fact that
deletions of the HMGI-C gene are responsible for the pigmy
phenotype in mouse. This is characterized by a reduced body size
(40% than normal) and a cell autonomous growth defect (Zhou
et al, 1995). Conversely, transgenic mice expressing a truncated
version of the HMGI-C protein display a giant phenotype (Battista
et al, 1999) and a high incidence of lipoma (Arlotta et al, 2000).
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Although in mammals most adult differentiated tissues express no
HMGI-C and little or no HMGI(Y) (Zhou et al, 1995; Chiappetta et
al, 1996; Hirning-Folz et al, 1998), wild-type or anomalous HMGI
proteins are heavily expressed in several benign and malignant
neoplasia. HMGI-C gene is frequently rearranged in most benign
mesenchymal tumours, and rearranged or amplified in sarcomas
and leukaemias (Schoenmakers et al, 1995; Kazmierczak et al,
1996; Berner et al, 1997; Rommel et al, 1997; Kottickal et al,
1998; Pedeutour et al, 2000). High levels of HMGI(Y) expression
have been identified in a number of transformed cell lines
(Giancotti et al, 1987). In vitro studies have shown that impair-
ment of the expression of HMGI proteins prevents oncoviral trans-
formation of rat thyroid cells (Giancotti et al, 1987; Berlingieri
et al, 1995), thus establishing a strong link between high level of
HMGI(Y) expression and transformed phenotype. A number of
studies have shown that HMGI(Y) expression is increased in
human epithelial tumours including thyroid, colorectal, uterine
cervix and prostate cancer (Chiappetta et al, 1995; Fedele et al,
1996; Tamimi et al, 1996; Bandiera et al, 1998). Extensive
analysis of thyroid and colorectal tumours brought to the conclu-
sion that quantitation of the level of HMGI(Y) expression in tissue
sections and/or RNA samples might provide a potential diagnostic
indicator (Chiappetta et al, 1998; Abe et al, 1999). In contrast,
scant attention has been paid to the biological role of HMGI
proteins in the nervous system and to the potential significance of
their expression for neural cell tumorigenesis.
In a previous study, we have addressed the question whether
expression of HMGI genes is altered in neuroblastic tumours. We
have shown that HMGI-C mRNA is expressed in a subset of NB
tumour specimens and only in NB cell lines resistant to the
antiproliferative and differentiative effects of RA (Giannini et al,
1999). HMGI-C has also been shown to impair RA-responsive-
ness, since its exogenous expression counteracts RA-mediated
growth inhibition in SY5Y NB cells (Giannini et al, 1999). In
contrast,  HMGI(Y) expression was detected in all NB tumours
and cell lines, although it is differentially regulated by RA in
RA-sensitive and -resistant cells. Thus, expression or regulation of
HMGI genes might be related to NB cell differentiation and
growth. In this paper we have extended these results by showing
that HMGI and HMGY isoforms are both expressed at the mRNA
and protein level in all NB cell lines and that both are further
upregulated by RA in RA-resistant NB cells. More interestingly,
we also show higher immunohistochemical expression of
HMGI(Y) protein in undifferentiated neuroblasts populating NB
tumours compared to more differentiated GNB and GN. Our
results suggest that HMGI(Y) expression should be regarded as
a potential diagnostic indicator of lack of differentiation of
neuroblastic tumours.
MATERIALS AND METHODS
Cell culture conditions
The human neuroblastoma cell lines SK-N-AS, SH-EP, KCNR,
SK-N-BE and SY5Y were cultured in RPMI 1640 medium (or E-
MEM for SK-N-SH) supplemented with 10% fetal bovine serum
(FBS), 2 mM glutamine, 50 units ml–1 penicillin, and 50 µ g ml–1
streptomycin at 37° C with 5% CO2. For stimulation experiments
cells were seeded at low density. All-trans retinoic acid (Sigma
Chemicals Co, St Louis, MO, 1 µ M) was added 24 hours after
seeding. On the basis of a time course analysis previously reported
(Giannini et al, 1999), the clearest results were observed after
24 hours of treatment for SK-N-AS, SH-EP and SK-N-SH. 48
hours of treatment were required to observe HMGI(Y) repression
in KCNR and SY5Y cells, while much longer treatment (10–14
days) was required for SK-N-BE cells.
RNA preparation and RT-PCR
Following treatment, cells were scraped from the dish, washed
twice with ice-cold PBS and processed for RNA extraction with
the RNAeasy kit (Quiagen Inc, Chatsworth, CA) according to the
manufacturer’s instructions. The RT reaction was performed on
total RNA (1 µ g) using the Moloney murine leukaemia virus
reverse transcriptase kit according to the manufacturer’s instruc-
tions (Life Technologies, Inc) in a final volume of 20 µ l for 45 min
at 42° C. An aliquot (2 µ l) of the RT reaction was subjected to a
semiquantitative PCR reaction (1 min at 94° C, 1 min at 58° C,
2 min at 72° C, for 20, 25 or 30 cycles) for HMGI(Y) amplification
with the specific primers HMGI(Y)#1, 5′ -CTGCTCCTCCTCC-
GAGGAC-3′ and HMGI(Y)#2 5′ -AAGATGAGTGAGTC-
GAGCTC-3′ , PCR products were electrophoresed on a 2.5%
Nusieve agarose gel and blotted on hybridization membranes
(Gene Screen Plus, NEN Life Science Product, Boston, MA). A
second PCR fragment amplified by using primers HMGI(Y)#PR,
5′ -CCTCCTTCACTGTTCCCTCT-3′ and HMGI(Y)#3, 5′ -TAC-
GGGGACTAGGGAAGTTG-3′ , was cloned, 32P-labelled and
subsequently used as internal probe for the hybridization of NB
tumour samples. 1/40 of the same RT reaction was subjected to a
semiquantitative PCR (1 min at 94° C, 1 min at 58° C, 2 min at
72° C, for 20, 25 or 30 cycles) to quantitatively amplify the β -actin
cDNA as a control using the specific primers: β -act#3,
5′ -CTACAATGAGCTGCGTGTGG-3′ ;  β -act#4, 5′ -CGGTGAG-
GATCTTCATGAGG-3′ ). Amplicons were electrophoresed,
blotted on nylon membranes and hybridized to a β -actin specific
probe.
Protein extraction and Western blot analysis
Total HMG proteins were selectively extracted by 5% (v/v)
perchloric acid from cells cultured as above and analysed by
Western blot as previously reported (Bandiera et al, 1998). Equal
amounts of proteins from the different control or RA-treated cell
lines were run on a 15% SDS-polyacrylamide gel in Tris/
ricine/SDS buffer. Coomassie staining of the higher parts of the
gels allowed the detection of the histone H1, that can be assumed
to be constantly expressed in different cell lines (Giancotti et al,
1993) and can be used to confirm the equal loading of the wells
(Bandiera et al, 1998). The lower part of the gels was transferred
by semi-dry blotting onto 0.1 µ M-pore PVDF Millipore
membranes. They were subsequently blocked in 5% non-fat dry
milk and incubated with rabbit polyclonal antibody developed
against a peptide derived from HMGI protein (Chiappetta et al,
1995; Bandiera et al, 1998). For the detection of specifically
recognized proteins, we took advantage of the SuperSignal
Substrate supplied by Pierce (Rockford, IL).
Immunohistochemistry of HMGI(Y)
A total of 11 cases of neuroblastic tumours were selected from the
file of the Department of Pathology, Seoul National University
Children’s Hospital, and 5 µ m-thick sections were obtained fromHMGI genes and neuroblastic tumours 1505
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representative paraffin blocks. Sections were deparaffinized and
hydrated with xylene and graded alcohol respectively. Endogenous
peroxidase was quenched with 3.0% hydrogen peroxide in ethanol
for 10 minutes. After PBS rinses, the sections were incubated
overnight at 4° C with 1:100 diluted rabbit anti-HMGI(Y)
(Chiappetta et al, 1995; Bandiera et al, 1998). Detection was
performed using a large volume DAKO LSAB kit (DAKO A/S,
Glostrup, DK). Linking agent (the biotinylated anti-rabbit and
anti-mouse immunoglobulins contained in the kit and diluted in
PBS) and streptavidin conjugated to horseradish peroxidase in
Tris-HCl buffer were sequentially applied for 30 minutes. PBS
rinsing was performed between each step. 3,3′ -diaminobenzidine
was used as chromogen, and counterstaining was done with
Meyer’s haematoxylin. Immunoreactivity was graded according
to the fraction of positive undifferentiated or neuronal cells; +:
>10–30%, ++: 30–60%, +++: ≥ 60%.
RESULTS
Expression of HMGI and HMGY isoforms in NB cell
lines
We have recently reported the expression of the HMGI(Y) and
HMGI-C gene in human neuroblastoma cell lines and tumours
using Northern blot and RT-PCR. In addition, we have also
reported that HMGI(Y) expression can be modulated by retinoic
acid (Giannini et al, 1999). However, none of the assays we previ-
ously used could reveal which of the two isoforms of the gene,
namely HMGI or HMGY, was expressed in NB and modulated by
RA. Therefore we performed RT-PCR on total RNA extracted
from RA-treated or control NB cells, using two primers which
could amplify the entire coding sequence of the HMGI(Y) gene
under exponential amplification conditions. The PCR products
were electrophoretically run, blotted and hybridized to a specific
probe. Even though the modifications of HMGI(Y) expression in
response to RA were better appreciated by a more quantitative
methodology as Northern blot (Giannini et al, 1999), under the
present experimental conditions we could easily discriminate
between the two isoforms (Figure 1A). One of three identical
experiments we performed is illustrated in Figure 1. The data
confirmed and extended our previous results, since we found that
both HMGI and HMGY are clearly expressed in all the cell lines
analysed (Figure 1). We also confirmed that their expression could
be positively modulated by RA in SK-N-AS, SK-N-SH and SH-
EP cells which fail to undergo growth arrest and differentiation
following RA treatment (Giannini et al, 1999). Conversely, HMGI
and HMGY isoforms are slightly repressed by RA in SY5Y,
KCNR and SK-N-BE cells (Figure 1A). Densitometric analysis of
the blots indicated that HMGI transcript expression is on average 2
fold higher than HMGY (Figure 1B). Although RA treatment did
not induce high variations in the ratio between the two isoforms,
some minor differences could be noted. It appeared that the ratio
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Figure 1 RT-PCR analysis of HMGI and HMGY expression in NB cell lines. RT-PCR analysis was performed on total RNA extracted from control or
RA-treated NB cells by amplification of the entire coding sequence and electrophoretic run on a 2.5% agarose gel. The amplification products were then blotted
and hybridized to a specific HMGI(Y) probe as reported in material and methods. (A) Exemplification of one of three different RT-PCR amplifications performed
on the same RNAs in which HMGI and HMGY amplicons can be clearly distinguished after hybridization. (B) After the densitometric scanning of the X-ray films,
the ratio between HMGI and HMGY intensity values was calculated for each lane and has been reported graphically. HMGI intensity is on average 2 times
HMGY and the ratio is only poorly affected by RA in most NB cell lines.between HMGI versus HMGY expression is slightly increased by
RA in KCNR, SK-N-BE, SK-N-AS cell lines, did not vary in
SY5Y and SH-EP, and was slightly reduced in SK-N-SH (Figure
1B).
The regulation of HMGI and HMGY expression by RA was
also studied at the protein expression level by Western blot. The
specific polyclonal antibodies (Chiappetta et al, 1995; Bandiera et
al, 1998) detected both HMGI and HMGY expression in all the
cell lines (Figure 2). In SK-N-SH, we detected a clear increase of
both HMGI and HMGY isoforms after 1 day of RA treatment and
SK-N-AS showed sustained increase in both isoforms between
2 and 4 days of RA treatment (Figure 2). In contrast we only
observed very minor variations of HMGI and HMGY protein
expression in KCNR and SY5Y cells (Figure 2). The same
membranes were subsequently probed with anti-HMGI-C specific
antibodies. As much as its RNA counterpart (Giannini et al, 1999),
HMGI-C protein was absent in KCNR and SY5Y and constitu-
tively expressed in SK-N-AS and SK-N-SH, where it was not
affected by RA (Figure 2).
Expression of HMGI(Y) in neuroblastic tumours
Besides its expression in NB cell lines, we have recently observed
the expression of HMGI(Y) transcripts in 23 out of 23 (100%)
neuroblastoma cases, through a sensitive RT-PCR approach
(Giannini et al, 1999). More recently we have extended this
analysis to a total of 65 samples, confirming HMGI(Y) expression
in all the RNA samples extracted from NB tumour specimens (not
shown). However this method did not allow us to determine which
of the different cell types commonly present within the tumour
mass is responsible for HMGI(Y) expression, neither was it
compatible with an accurate quantitative analysis of its expression.
To gain such information and to provide more stringent evidence
on  HMGI(Y) expression, we have used specific antibodies to
perform immunohistochemistry on a number of neuroblastic
tumours.
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Figure 2 Western blot analysis of HMGI and HMGY expression in NB cell
lines. Appropriate electrophoretic and blotting conditions were used to
resolve HMGI and HMGY bands. Equal loading of the lanes was confirmed
by the equal intensity of the histone H1 bands observed in the Coomassie-
stained upper portion of the gels (see Materials and methods). The
membranes were probed with the specific anti-HMGI(Y) antibody and the two
isoforms can be clearly distinguished. HMGI and HMGY expression was
analysed at different time points after RA treatment. Only informative time
points are reported; 24 hours of RA treatment are enough to detect a strong
increase of both HMGI and HMGY in SK-N-SH cells. A sustained increase in
both proteins is observed in 2 and 4 days RA-treated SK-N-AS cells. Only a
slight decrease in HMGI and HMGY proteins could be detected in KCNR and
SY5Y cells even after longer exposure to RA. The same membranes were
also used to assess HMGI-C expression, which, as expected is not
expressed in SY5Y and KCNR cells and is constitutively expressed in
SK-N-AS and SK-N-SH cells.
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Figure 3 Immunohistochemical staining for HMGI(Y) in neuroblastic tumours. Nuclear expression of HMGI(Y) in neuroblastic tumours declines as the cells
undergo neuronal differentiation. The sections were counterstained with Meyer’s haematoxylin. (A, B) In undifferentiated neuroblastomas, strong nuclear
immunoreactivity is found in the majority of the neuroblastic cells (white arrowheads). (C) In ganglioneuroblastoma, differentiating neuronal cells (white
arrowheads) and some Schwannian cells (black arrowheads) are positive for HMGI-Y while differentiated ganglion cells are negative. (D) Significant
immunoreactivity is not detected in terminally differentiated ganglionic cells (white arrowheads) of ganglioneuroma. (Magnification: × 200.)HMGI genes and neuroblastic tumours 1507
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In agreement with previous results, the typical nuclear expres-
sion of HMGI(Y) was found in all the 11 cases analysed (Table 1
and Figure 3). However, we observed marked differences in the
immunoreactivity within the different cell populations of the same
tumour, and between tumours with different histological appear-
ance. In fact, while we generally observed a strong immunoreac-
tivity in a majority of undifferentiated neuroblastoma cells, we
detected a much lower number of immunoreactive cells in more
differentiated tumours (Table 1 and Figure 3). The undifferentiated
cells in neuroblastomas showed strong and diffuse nuclear staining
(Figure 3A, B). In ganglioneuroblastomas, neuronally differenti-
ating cells were positive for HMGI(Y), but immunoreactivity was
weaker in cells having more differentiated phenotype (Figure 3C).
Occasional Schwann cells were also positive for HMGI(Y) (Figure
3C). The terminally differentiated neuronal cells mostly present in
ganglioneuromas were generally negative and only scant neuronal
cells showed very weak or hardly discernible immunoreactivity
(Figure 3D).
DISCUSSION
In a previous study we described the expression of HMGI family
members in NB cell lines and tumours and suggested their
involvement in determining retinoic acid resistance in NB cell
lines (Giannini et al, 1999). The work presented here largely
extends and completes our previous report, by adding information
on the expression of the different HMGI isoforms at both the
mRNA and protein level and by including the immunohisto-
chemical characterization of HMGI(Y) expression in neuroblastic
tumours, thus providing interesting insights for both NB tumour
biology and diagnosis.
NB shows a very high incidence of spontaneous regression and
differentiation in infants (Bolande, 1985). Probably reflecting this
feature, many cultured NB cell lines can be induced to undergo
growth arrest and differentiate by a variety of agents, including RA
(Albemayor and Sidell, 1989; Thiele, 1991b). This process is
accompanied by the regulation of the expression of several genes
at the transcriptional and post-transcriptional level. Repression of
c-myc or mycN (in MYCN amplified cell lines) (Thiele et al,
1985), increase in Trk receptors (Brodeur et al, 1997) and inhibi-
tion of cell cycle progression mostly due to an increase in the
cyclin dependent kinase inhibitor p27 (Matsuo and Thiele, 1998),
are associated and at least in part responsible for the biological
responses of NB cells to RA. Inability to morphologically
differentiate into more neuronal phenotypes and attain a complete
arrest in the G0 phase of the cell cycle in response to RA has also
been described for several NB cell lines. These cells are referred to
as RA-resistant, even though they are still capable of transducing
RA-dependent signals. We have recently shown that RA represses
HMGI(Y) mRNA expression in RA-sensitive cells, while it
increases HMGI(Y) mRNA in RA-resistant NB cells (Giannini et
al, 1999). Here we have confirmed that this increase occurs for
both HMGI and HMGY isoforms at the RNA and protein level.
We presented also evidence that HMGI-C protein is heavily
expressed in RA-resistant cells. Taken together these observations
suggest that high levels of HMGI family members may be in part
responsible for the resistance to RA-dependent growth inhibition
in cells like SK-N-AS or SK-N-SH. Alternatively, since these cell
lines do not undergo RA-dependent neuronal differentiation, but
still respond to RA with respect to additional biological parameters
(i.e., genomic responses), the increase in HMGI and -Y proteins
might occur as a part of a growth/differentiation programme
alternative to the neuronal differentiation pathway. In any case it is
interesting to note that, although HMGI expression is higher than
HMGY in all cell lines, RA does not significantly modify the ratio
between the two isoforms. This is compatible with the hypothesis
that most of the RA effect occurs at the level of transcription of the
common unspliced precursor transcript (G. Giannini, unpublished
data). Therefore RA appears to act differently than the phorbol
esther TPA that preferentially increases HMGY expression in
transformation sensitive JB6 cells (Cmarik et al, 1998). Whether
HMGI and HMGY perform identical or different biological
activities in NB cells or elsewhere, still remains elusive.
In analysing HMGI(Y) expression in RA-sensitive cell lines, we
have observed that both HMGI and HMGY mRNA are reduced by
RA, and that the ratio between the two isoforms is not significantly
modified. In contrast, we could not detect a strong decrease at the
protein level. The failure to identify a consistent reduction of
HMGI and/or HMGY proteins in RA-sensitive cells could be
partially explained by the prolonged stability of these molecules
(Holth et al, 1997). It is alo possible that HMGI(Y) mRNA reduc-
tion by RA is a consequence more than a cause of the growth arrest
and neuronal differentiation induced by RA, and that a sudden
reduction in HMGI and -Y proteins is not required for these
processes to occur. Consistent with this hypothesis, exogenous
expression of an HMGI-GFP construct in RA-sensitive SY5Y
cells did not affect RA sensitivity (Giannini et al, 1999). In any
case, although the biological significance of reduced HMGI(Y)
expression in more differentiated neuroblastic cells remained
Table 1 Expression of HMGI(Y) in neuroblastic tumours (n = 11)
Case no. Sex/Age Stage Histology HMGI(Y) MYCN
1 M/3 mo. 2 NB ++ non-amplified
2 M/17 mo. 4 NB +++ amplified
3 F/9 mo. 4 NB +++ non-amplified
4 M/10 mo. 3 NB ++ non-amplified
5 F/19 mo. 4 NB ++ amplified
6 F/12 mo. 2 GNB ++ non-amplified
7 F/37 mo. 3 GNB + non-amplified
8 M/20 mo. 4 GNB + non-amplified
9 F/19 mo. 4 GN + non-amplified
10 F/60 mo. 4 GN + non-amplified
11 F/13 mo. 4 GN + non-amplified
mo., months; NB, neuroblastoma; GNB, ganglioneuroblastoma; GN, ganglioneuroma. +: >10–30%, ++: 30–60%, +++: ≥ 60%
(immunoreactivity in undifferentiated or neuronal cells).1508 G Giannini et al
British Journal of Cancer (2000) 83(11), 1503–1509 © 2000 Cancer Research Campaign
elusive thus far, the association between neuroblastic differentia-
tion and low levels of HMGI(Y) expression is also confirmed by
our immunohistochemical analysis on neuroblastic tumours. In
fact, we also show that in vivo, higher HMGI(Y) expression is
observed in less differentiated phenotypes, while neuronally
differentiated cells only have scant expression of HMGI(Y), if any.
High levels of HMGI(Y) expression have been associated with
advanced grade tumours both in vitro and in vivo. The extensive
analysis of its expression in thyroid, colorectal and uterine cervix
cancers has indicated its possible role as a diagnostic and possibly
as a prognostic factor (Chiappetta et al, 1995, 1998; Fedele et al,
1996; Tamimi et al, 1996; Bandiera et al, 1998; Abe et al, 1999).
Stratification of neuroblastic tumour (NT) patients is currently
based on the examination of a large panel of clinical, histopatho-
logical and molecular parameters, including patient age and stage,
levels of serum factors (ferritin, neuron specific enolase, etc.),
degree of neuroblastic differentiation and Schwannian/stroma
components, presence of MYCN amplification, ploidy, chromo-
some 1p deletions, expression of specific genes like the NGF
receptor TrkA, and protein involved in multidrug resistance
(MDR1 and MRP) (reviewed in Castleberry, 1997; Katzenstein et
al, 1998; Shimada et al, 1999). Although many of these markers
have been shown to be predictive of the patient outcome, many of
them are not independent. Among the molecular markers, detec-
tion of MYCN amplification appears to be the most reliable nega-
tive prognostic indicator (Seeger et al, 1985; Katzenstein et al,
1998). However, although most patients with favourable histology
do not show MYCN amplification, a consistent number of
unfavourable histology cases also show no MYCN amplification,
suggesting that additional parameters are still required for a better
stratification of NT patients (Castleberry, 1997). We have shown
that, similar to other cancers, HMGI(Y) is expressed in all NT
studied by RT-PCR or immunohistochemistry, with higher expres-
sion in less differentiated and more aggressive NB tumours
compared to GNB and GN. The higher levels of HMGI(Y) expres-
sion seem to be independent from MYCN amplification. Therefore,
although our observations need to be extended to larger series of
patients, they strongly suggest that the expression of HMGI(Y)
might represent a potential parameter to be evaluated in the
stratification of NT patients.
Despite its proven effect on several NB cell lines and its
valuable employment in the treatment of a number of malignan-
cies, the efficacy of retinoic acid treatment in NB patients is still
controversial (Finklestein et al, 1992; Adamson et al, 1997). As
reported in a very recent study, treatment of high-risk neuro-
blastoma cases with 13-cis-RA following either bone marrow
transplantation or intense chemotherapy produced a significant
amelioration of the 3-year event-free survival (Matthay et al,
1999). However not all patients appeared equally sensitive to RA
treatment. Only patients with minimal residual disease benefited
from such treatment (Matthay et al, 1999). Our results point out
that quantitative and qualitative differences exist in the pattern of
expression of the HMGI proteins among different NB cell lines
and neuroblastic tumours. Furthermore, high expression of HMGI-
C and induction of HMGI(Y) by RA are associated with and
partially responsible for NB cell resistance to the antiproliferative
effect of RA in vitro. If the association between the increased
expression of the HMGI family members and the reduced sensi-
tivity to RA should be confirmed also in vivo, this parameter could
help in predicting which cases might benefit from a RA-based
therapeutical approach.
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